Global Live Biotherapeutic Product Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1300
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global live biotherapeutic product (LBP) market are:
Increasing incidence of digestive disorders
Increasing healthcare expenditure and growing awareness
Innovative technology
The following are the primary obstacles to the live biotherapeutic product (LBP) market’s expansion:
High manufacturing cost
Strict regulatory compliance
Lack of infrastructure
Future expansion opportunities for the global live biotherapeutic product (LBP) market include:
Increasing strategic partnerships with biotech companies
A growing interest in customized treatment
Increased investment in research and development
Key Industry Insights & Findings from the Report:
The live biotherapeutic product (LBP) market is expanding rapidly due to improvements in the study of the microbiome and rising spending on customized treatment.
The market for live biotherapeutic products (LBP) is driven by technological developments, heightened awareness of healthcare, and supportive government policies.
North America dominated the market and accounted for a revenue share of global revenue in 2023.
One of the significant concerns restraining industry growth is the high manufacturing cost.
Market Analysis:
The live biotherapeutic product (LBP) market is driven by growing demand for tailored medication, increased awareness of gut health, and developments in microbiome research. The market is expanding due to the rising incidence of immune-related disorders, metabolic diseases, and gastrointestinal disorders.
Furthermore, live biotherapeutic products (LBP) are a promising field in contemporary healthcare because of significant R&D investment, regulatory support for microbiome-based therapeutics, and the shift toward non-antibiotic treatments.
List of Prominent Players in the Live Biotherapeutic Product (LBP) Market:
Seres Therapeutics, Inc.
Microbiotica
Enterome
Destiny Pharma plc
Taisho Pharmaceutical Holdings
AOBiome Therapeutics, Inc.
Finch Therapeutics Group, Inc
Ferring Pharmaceuticals
Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
MaaT Pharma
Vedanta Biosciences Inc.
OxThera AB
Pendulum Therapeutics
Caelus Health
Quorum Innovations
Sanofi S.A
DermBiont, Inc.
EnteroBiotix Ltd
YSOPIA Bioscience
Winclove Probiotics
TargEDys
Evelo Biosciences, Inc.
BiomX
Biomica Ltd.
Scioto Biosciences, Inc.
Lactobio A/S
Takeda Pharmaceutical Co. Ltd.
Second Genome Therapeutics
Johnson and Johnson Inc.
Kaleido Biosciences Inc.
OptiBiotix Health Plc
PureTech Health Plc
Immuron Limited
Naked Biome
Synthetic Biologics
ExeGi Pharma
Nexbiome
Mybiotics Pharma LTD.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03
Recent Developments:
In January 2025, Microbiotica, a clinical-stage biopharma company that is creating a pipeline of oral precision microbiome medications known as live biotherapeutic products (LBPs), presented new information at the Keystone Symposia Human Microbiome.
In December 2024, DermBiont, a clinical-stage biotechnology company, provided updates on its development pipeline. These included the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs and expected clinical milestones. Vermont is developing targeted topical therapeutics to address patient needs in three of the most commonly diagnosed dermatological indications.
In September 2024, to treat patients with recurrent glioblastoma, Enterome, a clinical-stage company that is creating first-in-class immunomodulatory medications for solid and liquid cancers and inflammatory diseases using its proprietary Mimicry platform, announced the database lock of its Phase 2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/an anti-VEGF therapy (bevacizumab).
Live Biotherapeutic Product (LBP) Market Dynamics:
Market Drivers: Increasing Incidence of Digestive Disorders
One of the main factors propelling the live biotherapeutic product (LBP) market is the rising prevalence of intestinal microbiota abnormalities and digestive illnesses.
The need for treatments based on the microbiota is growing as gastrointestinal disorders become more common. Moreover, LBPs provide tailored, non-antibiotic therapies that improve patient outcomes by restoring gut health. Market expansion is further accelerated by rising awareness and research on the gut microbiota, which further encourages adoption.
Challenges: High Manufacturing Cost
One significant barrier to market expansion because of the high cost of manufacturing. The development of microbiome-based treatments raises production costs since it requires specialized facilities, sophisticated bioprocessing methods, and stringent quality control procedures.
Furthermore, LBPs are less available due to additional expenses associated with clinical studies, regulatory compliance, and storage restrictions. Moreover, despite the rising need for treatments that target the microbiome, these financial obstacles restrict development and uptake, which slows market growth.
North America Is Expected To Grow With The Highest CAGR During The Forecast Period
The North American live biotherapeutic product (LBP) market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. This is because of the growing demand for personalized therapy, the incidence of digestive problems, and developments in microbiome research. Moreover, strong R&D expenditures and a thriving biotech sector all contribute to market growth.
The regions leadership in LBP development is also a result of expanded clinical trials, rising consumer awareness of gut health, and partnerships between biotech and pharmaceutical businesses, ensuring North Americas place as an important marketplace.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1300
Segmentation of Live Biotherapeutic Product (LBP) Market-
By Product-
VOWST (SER-109)
REBYOTA
Visbiome
Other Pipeline Products
By Target Disease Indication-
Recurrent C. Difficile Infection
Irritable Bowel Syndrome (IBS)
Ulcerative Colitis (UC)
Antibiotic-associated diarrhea (AAD)
Pouchitis
Hepatic Encephalopathy (HE)
Graft Versus Host Disease
Necrotizing Enterocolitis
Primary Hyperoxaluria
Others
By Route of Administration-
Hospitals
Diagnostic Laboratories
Oral Therapeutics
Rectal Therapeutics
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
